Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature. Issue 7 (July 2015)

• Record Type: Journal Article
• Authors: Börschel, Niklas; Schwöppe, Christian; Zerbst, Caroline; Angenendt, Linus; Kessler, Torsten; Klapper, Wolfram; Giovannoni, Leonardo; Elia, Giuliano; Neri, Dario; Berdel, Wolfgang E.; Mesters, Rolf M.; Schliemann, Christoph
• Is Part Of: Leukemia research. Volume 39:Issue 7(2015:Jul.)
• Page Start: 739
• Page End: 748
• Publication Date: 2015-07
• Subjects: Leukemia -- Periodicals; Leukemia -- Periodicals; Leucémie -- Périodiques; Leukemia; Periodicals; Electronic journals; Electronic journals; 616.9941905
• DOI: 10.1016/j.leukres.2015.04.005
• Languages: English
• ISSNs: 0145-2126

Abstract

<abstract abstract-type="author-highlights" id="abs0005"> <title id="sect0005">Highlights</title> <sec> <p id="spar0005"> <list id="lis0005"> <list-item id="lsti0005"> <label></label> <p id="par0005">L19-IL2 is a fully human immunocytokine that targets EDB-Fn positive blood vessels.</p> </list-item> <list-item id="lsti0010"> <label></label> <p id="par0010">L19-IL2 efficiently homes to angiogenic vessels in mantle cell lymphomas (MCL) in mice.</p> </list-item> <list-item id="lsti0015"> <label></label> <p id="par0015">The antibody-mediated accumulation of IL-2 recruits immune cells to the lymphoma tissue.</p> </list-item> <list-item id="lsti0020"> <label></label> <p id="par0020">L19-IL2 strongly potentiates the activity of anti-CD20 immunotherapy against MCL xenografts.</p> </list-item> <list-item id="lsti0025"> <label></label> <p id="par0025">EDB-Fn is expressed in the vasculature of human MCL samples.</p> </list-item> </list> </p> </sec> </abstract>